Drug intelligence / Profile preview

PA-1050040

Development stage: Discontinued
Lead developer: Panacos Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

PA-1050040 is a second-generation HIV-1 maturation inhibitor and a chemical analog of bevirimat (BVM). It acts by inhibiting the replication of HIV-1 through modulation of the viral Gag gene products, specifically interfering with virus maturation. This mechanism disrupts the proper processing of the Gag polyprotein, which is essential for producing infectious viral particles. The drug was initially developed by Panacos Pharmaceuticals as part of their efforts to create small-molecule oral drugs targeting various stages in the HIV life cycle, particularly virus maturation. Development was discontinued before approval[1][2][4][5].

Other names: PA1050040PA-1050040PA 1050040

Targets

Gag (HIV-1 Gag polyprotein)

Beyond the preview

Go deeper on PA-1050040.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PA-1050040.

Explore the full profile